Format

Send to

Choose Destination
ACS Infect Dis. 2020 Jan 10;6(1):3-13. doi: 10.1021/acsinfecdis.9b00371. Epub 2019 Dec 6.

Setting Our Sights on Infectious Diseases.

Author information

1
Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery , University of Dundee , Dundee DD1 5EH , United Kingdom.
2
Tufts University School of Medicine , 136 Harrison Avenue , Boston , Massachusetts 02111 , United States.
3
Department of Chemistry , University of Ghana , P.O. Box LG56, Legon, Accra , Ghana.
4
National Institute of Allergy and Infectious Diseases , National Institutes of Health , 9000 Rockville Pike , Bethesda , Maryland 20892 , United States.
5
Center for Emerging and Re-emerging Infectious Diseases (CERID) , University of Washington , MS 358061, 750 Republican Street , Rm E-606, Seattle , Washington 98109-4766 , United States.
6
School of Humanities , University of Glasgow , 1 University Gardens , Glasgow G12 8QQ , United Kingdom.
7
Medicines for Malaria Venture (MMV) , PO Box 1826, 20 Route de Pré-Bois , 1215 Geneva 15, Switzerland.
8
Helmholtz Institute for Pharmaceutical Research Saarland, Department Microbial Natural Products , Saarland University , Campus E8.1, 66123 Saarbrücken , Germany.
9
German Centre for Infection Research , partner site Hannover-Braunschweig , Germany.
10
Independent Consultant, Switzerland.
11
Institute of Translational Medicine , University of Liverpool , Liverpool L69 3BX , United Kingdom.
12
Department of Medical Parasitology and Infection Biology , Swiss Tropical and Public Health Institute , Socinstrasse 57 , CH-4051 Basel , Switzerland.
13
University of Basel , CH-4001 Basel , Switzerland.
14
Tres Cantos Medicines Development Campus, Diseases of the Developing World (DDW) , GlaxoSmithKline , Tres Cantos , Spain.
15
Paul Leeson Consulting Ltd. , United Kingdom.
16
Novartis Institute for Tropical Diseases (NITD) , Novartis Institutes for BioMedical Research (NIBR) , 5300 Chiron Way , Emeryville , California 94608 , United States.
17
QIMR Berghofer Medical Research Institute , 300 Herston Road , Hertson , Queensland 4006 , Australia.
18
SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit, Institute of Infectious Disease and Molecular Medicine and Wellcome Centre for Infectious Disease Research in Africa , University of Cape Town , Observatory, Cape Town 7925 , South Africa.
19
Biofilm Study Group , Institute of Molecular Biology and Genetics of National Academy of Sciences of Ukraine , 150 Zabolotnoho Street , Kiev 03143 , Ukraine.
20
School of Engineering , Massachusetts Institute of Technology , Building 1-206, 77 Massachusetts Avenue , Cambridge , Massachusetts 02139-4307 , United States.
21
Medicines Discovery Catapult , Alderley Park, Alderley Edge, Cheshire SK10 4TG , United Kingdom.
22
ViiV Healthcare , 980 Great West Road , Brentford , Middlesex TW8 9GS , United Kingdom.
23
Drugs for Neglected Diseases Initiative (DNDi) , Chemin Louis-Dunant 15 , 1202 Genève , Switzerland.
24
LL Silver Consulting , New Jersey , United States.
25
Lancaster Institute for the Contemporary Arts (LICA), The LICA Building , Lancaster University , Lancaster LA1 4YW , United Kingdom.
26
Global Health Institute of Merck, Ares Trading S.A. , a subsidiary of Merck KGaA Darmstadt Germany , Route de Crassier 1 , 1262 Eysins , Switzerland.
27
Department of Medicine, Institute of Medical Sciences , Banaras Hindu University , Varanasi 221005 , India.
28
Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine , Mahidol University , 3/F, 60th Anniversary Chalermprakiat Building, 420/6 Rajvithi Road , Bangkok 10400, Thailand.

Abstract

In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center